Names and pronunciation
(a-due-KAN-ue-mab-avwa) Aduhelm
PDF page 40
Loading InternPractice…
Drug reference
(a-due-KAN-ue-mab-avwa) Aduhelm
PDF page 40
Func. class.: Alzheimer agent
PDF page 40
Chem. class.: Amyloid beta–directed antibody
PDF page 40
ACTION: A human immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against amy- loid beta, reduces amyloid beta plaques
PDF page 40
USES: Alzheimer disease
PDF page 40
CONTRAINDICATIONS None Precautions: Amyloid-related imaging abnormalities (ARIAs), hypersensitivity, angioedema
PDF page 40
SIDE EFFECTS CNS: Headache CV: Edema HEMA: Microhemorrhage MS: Falls Syst: ARIA
PDF page 40
INTERACTIONS None known
PDF page 40
DOSAGE AND ROUTES • Adult: IV Titration, 1 mg/kg IV over 1 hour every 4 weeks and at least 21 days apart for infusions 1 and 2; then 3 mg/kg IV over 1 hour every 4 weeks and at least 21 days apart for infusions 3 and 4; and then 6 mg/kg IV over 1 hour every 4 weeks and at least 21 days apart for infusions 5 and 6
PDF page 40
Available forms: Injection 170 mg/1.7 mL (100 mg/mL), 300 mg/3 mL (100 mg/mL) solution single-dose vials
PDF page 40
Administer: • Titrate • Obtain a recent (within 1 yr) brain MRI before use and before the 7th and 12th infusions. If severe ARIA-H is observed, may continue with caution only after a clinical evaluation and a follow-up MRI demonstrate radiographic stabilization • Dilution in 100 mL of 0.9% Sodium Chloride Injection, USP, is required be- fore administration. Give over 1 hr, use a 0.2- or 0.22-micron in-line filter • Storage: Store in original carton until use, protect from light, refrigerated, do not freeze or shake; combined time out of refrigeration with protection from light max 24 hr at room temperature
PDF page 40
Assess: • ARIA: Assess for headache, confu- sion, dizziness, vision changes, nausea; notify prescriber • Hypersensitivity: Assess for itching, rash, angioedema
PDF page 40
Evaluate: • Therapeutic response: Decreasing symptoms of Alzheimer disease (confu- sion)
PDF page 40
CLINICAL CONSIDERATIONS
PDF page 40
Patient and caregiver information: • ARIA: Teach patient that ARIA may occur with temporary swelling in areas of the brain, small spots of bleeding on the brain; to re- port headache, confusion, dizziness, vision changes, nausea. That MRIs will be needed • Hypersensitivity: Inform patient that hypersensitivity, including angioedema, urticaria, may occur, to contact health care provider
PDF page 41
PHARMACOKINETICS Onset, peak, duration unknown
PDF page 40
• Adult: IV Titration, 1 mg/kg IV over 1 hour every 4 weeks and at least 21 days apart for infusions 1 and 2; then 3 mg/kg IV over 1 hour every 4 weeks and at least 21 days apart for infusions 3 and 4; and then 6 mg/kg IV over 1 hour every 4 weeks and at least 21 days apart for infusions 5 and 6
PDF page 40